OMND Stock Overview
Provides psychedelic therapies in Canada. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Optimind Pharma Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.005 |
52 Week High | CA$0.01 |
52 Week Low | CA$0.005 |
Beta | 1.04 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.67% |
Recent News & Updates
Recent updates
Shareholder Returns
OMND | CA Healthcare | CA Market | |
---|---|---|---|
7D | 0% | 0.8% | 2.0% |
1Y | n/a | 33.4% | 17.5% |
Return vs Industry: Insufficient data to determine how OMND performed against the Canadian Healthcare industry.
Return vs Market: Insufficient data to determine how OMND performed against the Canadian Market.
Price Volatility
OMND volatility | |
---|---|
OMND Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 4.3% |
Market Average Movement | 8.1% |
10% most volatile stocks in CA Market | 18.4% |
10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: OMND's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine OMND's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | David Goodman | optimindpharma.com |
Optimind Pharma Corp. provides psychedelic therapies in Canada. The company offers psychedelic-like therapies for treatment of post-traumatic stress syndrome, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It also provides medical cannabis and other alternative treatments for various medical ailments through its clinic.
Optimind Pharma Corp. Fundamentals Summary
OMND fundamental statistics | |
---|---|
Market cap | CA$548.94k |
Earnings (TTM) | -CA$990.49k |
Revenue (TTM) | CA$111.44k |
4.9x
P/S Ratio-0.6x
P/E RatioIs OMND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OMND income statement (TTM) | |
---|---|
Revenue | CA$111.44k |
Cost of Revenue | CA$41.14k |
Gross Profit | CA$70.31k |
Other Expenses | CA$1.06m |
Earnings | -CA$990.49k |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.009 |
Gross Margin | 63.09% |
Net Profit Margin | -888.78% |
Debt/Equity Ratio | -321.5% |
How did OMND perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/23 21:02 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/08/31 |
Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Optimind Pharma Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|